On May 4, 2021 Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") reported that it has completed a Private Placement ("Placement") of new shares to new and existing institutional and sophisticated investors (Press release, Amplia Therapeutics, MAY 4, 2021, View Source;TE [SID1234579120]). The Placement will raise a total of approximately $3.8 million at an issue price of $0.23 per new, fully paid, ordinary share representing a 10.0% discount to the 15-day volume weighted price of shares traded up to 29 April 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A total of 16,585,000 new shares will be issued within the Company’s placement capacity under ASX Listing Rules 7.1 and 7.1A. The new shares are expected to be issued on 7 May 2021.

The placement was strongly supported by the Company’s largest shareholders, Platinum Investment Management Ltd. and Blueflag Holdings Pty Ltd. A new institutional shareholder, Acorn Capital, also participated in the Placement.

The proceeds from the Placement will be used to fund enabling activities for the Company’s planned Phase 2 clinical trials in pancreatic cancer and pulmonary fibrosis and provide working capital for the Company. The Phase 2 enabling activities include manufacture of drug substance and drug product, conduct of additional toxicology studies to support extended dosing in pulmonary fibrosis patients and clinical planning and lodgement of regulatory filings to support clinical trials in patients with pancreatic cancer.

Commenting on the results of the Placement, Amplia’s Chief Executive Officer DrJohn Lambert said "We are delighted to receive the continuing support of existing investors as well as to welcome new investors to our register. Over the last year, Amplia has put in place the necessary foundations for our planned Phase 2 clinical program for AMP945. Specifically, the recent completion of dosing in our Phase 1 trial of AMP945 together with the exciting results we have seen in our parallel non-clinical studies have provided the clinical safety data and preclinical rationale needed for us to push forward into Phase 2 clinical studies."

Taylor Collison acted as Lead Manager for the Placement.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

On May 4, 2021 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that management will be participating in fireside chats at the following investor conferences (Press release, Sangamo Therapeutics, MAY 4, 2021, View Source [SID1234579119]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BofA Securities 2021 Health Care Conference
Date: Thursday, May 13th at 1:15 p.m. Eastern Time
2021 RBC Capital Markets Global Healthcare Conference
Date: Tuesday, May 18th at 9:45 a.m. Eastern Time
For presentations that are webcast live, an access link will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. The presentations will also be available on the Sangamo Therapeutics website after the event.

On May 4, 2021 Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (Nasdaq: ZIO) reported that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, will present and participate in an upcoming panel discussion at the University of Pennsylvania’s upcoming Cellicon Valley symposium, May 6-7, 2021 (Press release, Ziopharm, MAY 4, 2021, View Source [SID1234579117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am excited to participate in this important event on behalf of Ziopharm," said Dr. Cooper. "This meeting will bring together a wide variety of leading thinkers and researchers, and I am looking forward to sharing my perspectives on Ziopharm’s unique technologies."

The panel session, entitled "Gene Delivery and Editing for Better CARs", will be moderated by Fyodor D. Urnov, PhD, Professor of Molecular and Cell Biology, University of California at Berkley.

Dr. Cooper’s remarks will focus on the advantages of Ziopharm’s cellular therapy technologies targeting solid tumors, including its proprietary non-viral gene transfer system, Sleeping Beauty.

Interested parties may register for the event using this link. Registrants will be able to view the event beginning at 9am ET on Thursday May 6, 2021, under Conference Track 3: Pre-Clinical / Manufacturing. The live Q&A will take place at 3:30pm ET also on May 6, 2021. Dr. Cooper’s slides will also be posted on the Ziopharm website in the Investors section.

On May 4, 2021 Veracyte, Inc. (Nasdaq: VCYT) reported that new data relating to the Prosigna Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Breast Cancer Virtual Congress 2021 taking place May 5-8 (Press release, Veracyte, MAY 4, 2021, View Source [SID1234579116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"New data accepted for presentation at this year’s ESMO (Free ESMO Whitepaper) Breast Cancer Congress provide further evidence for the importance of genomic testing in breast cancer, particularly to help physicians and patients make better informed treatment decisions based on the unique biology of individual patients’ tumors," said Bonnie Anderson, Veracyte’s chairman and chief executive officer. "We believe such data strengthen the backdrop for our Prosigna Breast Cancer Gene Signature Assay, and greatly appreciate the breast cancer experts who led and participated in these studies."

Following are details of the Prosigna-related posters accepted for presentation at the ESMO (Free ESMO Whitepaper) Breast Cancer Virtual Congress. These abstracts are available to meeting registrants on demand:

Title: Influence of PAM50 on therapeutic decisions in patients with early-stage Luminal Breast Cancer in a single centre

Poster: 62P

First Author: Alejandro Olivares-Hernandez, M.D., M.Sc., IBSAL – Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain

Title: Consensus on the utility of breast cancer multigene signatures in routine clinical practice among European Breast Cancer clinicians – The PROCURE project

Poster: 24P

First Author:

Giuseppe Curigliano, M.D., Ph.D., IEO – Istituto Europeo di Oncologia, Milan, Italy

The first poster will present findings from a prospective study conducted at the University Hospital of Salamanca (Spain), evaluating the influence of the PAM50 gene signature, the foundation of the Prosigna assay, on therapeutic decision-making for 143 patients with early-stage breast cancer.

The second poster will feature initial findings and consensus from the first wave of the PROCURE (Prosigna Clinical Utility Review) project, a European study utilizing the Delphi methodology to generate consensus regarding the clinical utility of genomic tests, including the Prosigna Breast Cancer Gene Signature Assay, in breast cancer treatment. The study is led by an independent scientific committee of eight breast cancer experts with input from 141 breast cancer clinicians practicing in nearly a dozen European countries.

About Prosigna

The Prosigna Breast Cancer Gene Signature Assay is a prognostic genomic test, built from PAM50 molecular subtypes, which combines tumor gene expression with clinicopathologic factors to better inform treatment decisions. The assay is indicated in female breast cancer patients who have undergone either mastectomy or breast-conserving therapy in conjunction with locoregional treatment consistent with standard of care, either as a prognostic indicator for distant recurrence-free survival at 10 years in post-menopausal women with Hormone Receptor-Positive (HR+), lymph node-negative, Stage I or II breast cancer, or lymph node-positive (1–3 positive nodes, or 4 or more positive nodes), Stage II or IIIA breast cancer to be treated with adjuvant endocrine therapy alone, when used in conjunction with other clinicopathological factors. Outside of the United States, the Prosigna Breast Cancer Gene Signature Assay also provides the intrinsic subtypes of the tumor tissue within three groups, low, intermediate and high, by the nCounter Analysis System through decentralized performance.

The Prosigna test is FDA 510(k) cleared in the United States for use on the nCounter Analysis System and is available for use when ordered by a physician. The Prosigna test has received CE Mark and is available for use by healthcare professionals in the European Union and other countries that recognize the CE Mark, as well as in Canada, Israel, Australia, New Zealand and Hong Kong. The assay is covered by Medicare and leading private payers in the United States, and is widely covered by government and private payers in the countries where it is available.

On May 4, 2021 VBL Therapeutics (Nasdaq: VBLT) reported that it will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open (Press release, VBL Therapeutics, MAY 4, 2021, View Source [SID1234579115]). Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financial Officer, will host a conference call at 8:30am EDT the same day to discuss the results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!